Pushing TXA in the Field: Dose, Timing, and the 3-Hour Window

The Cheapest Drug on the Truck That Actually Changes Outcomes

We carry a lot of expensive equipment. Tranexamic acid (TXA) is not one of them: it is an inexpensive generic that stores at room temperature and needs no cold chain. What it buys us, given correctly, is a measurable drop in death from hemorrhage. The catch is that "correctly" is mostly about the clock.

How TXA Actually Works

TXA is a synthetic lysine analog. It works by competitively binding the lysine-binding sites on plasminogen, blocking its conversion to plasmin. Plasmin is the enzyme that breaks down fibrin, so by inhibiting that step, TXA slows fibrinolysis and helps the clots we are forming stay formed.

This matters because severe trauma drives a hyperfibrinolytic state: the body starts dissolving its own clots at the worst possible moment. TXA is one of the few field interventions that directly attacks the coagulopathy leg of the lethal triad we treat with whole blood and active warming.

One regulatory detail worth knowing: the U.S. label for IV tranexamic acid (Cyklokapron) is for hemophilia patients undergoing tooth extraction. Trauma and postpartum hemorrhage use rests on the trial evidence below and on your medical director's protocol, not on the label indication.

The Evidence, Trial by Trial

CRASH-2 (Lancet, 2010) randomized 20,211 bleeding trauma patients in 40 countries and showed a reduction in all-cause mortality with TXA. The follow-up analysis of death due to bleeding by time to treatment is the one every medic should know:

WOMAN (Lancet, 2017) enrolled 20,060 women with postpartum hemorrhage. TXA reduced death due to bleeding (1.5% vs 1.9%), with the clearest effect when given within 3 hours of birth. It did not reduce hysterectomy or the composite primary endpoint.

The prehospital trials are where it gets honest:

• STAAMP (JAMA Surgery, 2020): 903 injured patients at risk for hemorrhage, 1 g given over 10 minutes during transport. Thirty-day mortality was 8.1% vs 9.9%, not statistically significant. In post hoc subgroups, TXA within 1 hour of injury (4.6% vs 7.6%) and in severe shock with SBP 70 or below (18.5% vs 35.5%) was associated with lower mortality.
• PATCH-Trauma (NEJM, 2023): 1,310 major trauma patients with suspected coagulopathy across 15 EMS systems in Australia, New Zealand, and Germany. TXA did not increase survival with a favorable functional outcome at 6 months (53.7% vs 53.5%). Death at 28 days was lower with TXA (17.3% vs 21.8%), and vascular occlusive events did not differ meaningfully.

Read together: TXA is safe to give early, the mortality signal is strongest in the first hour and in the sickest patients, and it is not a functional-outcome miracle.

Dose and the 3-Hour Window

The dosing most systems use traces back to CRASH-2: 1 g IV over roughly 10 minutes, followed by 1 g infused over 8 hours. Many EMS protocols give the 1 g bolus in the field and let the receiving facility run the maintenance dose; PATCH-Trauma used exactly that split. For postpartum hemorrhage, WOMAN gave 1 g IV, with a second 1 g if bleeding continued after 30 minutes or restarted within 24 hours.

The non-negotiable detail is timing:

• Give it early. The mortality benefit is concentrated when TXA is administered within 3 hours of injury, and is largest inside the first hour.
• The clock starts at injury, not at IV access. A 3-hour-old GSW that you just reached does not reset because you only now have a line.
• Late dosing can hurt. In CRASH-2, TXA given after the 3-hour mark was associated with increased death from bleeding, not benefit.

Field Practicalities and the Error We Keep Making

• Push it slow. The label limits undiluted TXA to no more than 1 mL per minute to avoid hypotension. At 100 mg/mL that is about 10 minutes for the 1 g bolus, so dilute it and run it rather than slamming it.
• Seizure risk is real but mostly a hospital problem: the label notes most TXA-associated seizures occurred during cardiovascular surgery at doses up to 10 times the standard dose, and after inadvertent neuraxial injection.
• Wrong-route deaths are real. In 2025 FDA added a Boxed Warning and made neuraxial injection a contraindication after TXA ampules were confused with local anesthetics and injected intrathecally, causing seizures, arrhythmias, and deaths. On our trucks the analogous risk is grabbing the wrong ampule from a crowded drug box. Read the label twice.
• Logistics win: unlike blood, TXA needs no cold chain. That makes it realistic to stock on nearly every ALS unit.

The takeaway for the field: TXA does not replace blood, and it does not replace controlling the bleeding. It is an early, time-boxed adjunct that is most useful in the first hour, exactly the window we own. A clean, time-stamped drug log on every push, with the time of injury documented next to it, is what lets the trauma team know precisely where in that window the patient sits.

Sources

• Lancet (PubMed) — CRASH-2: tranexamic acid in trauma patients with significant haemorrhage
• Lancet (PubMed) — CRASH-2 exploratory analysis: the importance of early treatment
• Lancet (PMC) — WOMAN trial: tranexamic acid in post-partum haemorrhage
• NEJM (PubMed) — PATCH-Trauma: prehospital tranexamic acid for severe trauma
• JAMA Surgery (PMC) — STAAMP: tranexamic acid during prehospital transport
• DailyMed — Cyklokapron (tranexamic acid) injection prescribing information